Company Overview
Jade Biosciences, Inc. functions as a biotechnology firm dedicated to the development of novel therapies targeting inflammation and immunology indications for patients suffering from autoimmune diseases. The company's primary asset is JADE101, a monoclonal antibody engineered to block the A PRoliferation Inducing Ligand protein, which is currently progressing through phase 1 clinical trials. Operating within the healthcare sector specifically under the biotechnology industry classification, the company focuses on advancing proprietary science to address complex autoimmune conditions. The firm currently employs 55 individuals and maintains a market capitalization of $653.93M, a valuation that reflects significant market interest despite the absence of reported annual revenue figures in the available data. This substantial market cap relative to an unlisted revenue stream suggests that the market is pricing the asset primarily on potential future clinical milestones and intellectual property value rather than current operational profitability.
Financial Health
The reported financial performance for Jade Biosciences, Inc. indicates a pre-profitability stage, with Net Income (TTM) recorded at $-100,136,000 and EBITDA standing at $-113,516,000. Revenue (TTM) is listed as N/A, which implies that the company has not generated sufficient commercial sales to offset its substantial operating expenses, resulting in the negative net income and EBITDA figures. This gap between nominal revenue and significant negative earnings highlights a cost structure dominated by research and development expenditures necessary to advance its pipeline through clinical phases. Free Cash Flow stands at $-61,221,752, a metric that indicates the company is consuming cash reserves to fund its operations and clinical trials rather than generating liquidity from business activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported as 0.0%, a figure that technically results from the division of negative income by revenue where revenue is effectively zero or negligible, indicating that the company is not yet producing profitable units at scale. The balance sheet shows a Cash position of $336.16M against a Debt level of $724,000, creating a highly conservative financial structure with a Debt to Equity ratio of 0.22. With a Current Ratio of 21.09, the company possesses immense short-term liquidity relative to its obligations, allowing for significant flexibility in funding R&D without the immediate pressure of debt service. Return on Equity is -89.2% and Return on Assets is -33.6%, metrics that reveal that management is currently utilizing the company's capital base to build a clinical pipeline rather than generating returns for shareholders, which is typical for early-stage biotechnology firms but confirms the absence of profitable operations.
Valuation Assessment
Trailing P/E and Forward P/E ratios are both N/A due to the company's negative earnings history, a situation common for biotechnology firms where valuation relies on alternative metrics rather than earnings multiples. The Price to Book ratio is 1.97, which indicates that the market values the company at nearly twice its book value, suggesting that investors are assigning a premium to the company's intangible assets and clinical pipeline potential. Price to Sales is N/A because there is no reported revenue, and the EV/EBITDA stands at -2.81, an alternative valuation metric that suggests the company's enterprise value is low relative to its negative earnings, though this comparison requires caution when earnings are deeply negative. The stock price has experienced significant volatility, with a 52-Week High of $100.10 and a 52-Week Low of $6.57. Without a specific current price provided in the source facts to calculate a precise percentage, the trading range itself indicates a wide variance in market sentiment, having moved from a low of $6.57 to a high of $100.10 over the last year. Beta is listed as N/A, meaning that standard volatility relative to the broader market cannot be quantified with the available data, though the wide 52-week range suggests high sensitivity to clinical trial news and sector trends.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, as the company has not yet established a consistent revenue stream or earnings history to calculate year-over-year percentage changes. In the absence of positive earnings, the concept of earnings growing faster or slower than revenue does not apply in a traditional sense, as the primary driver of value is the progression of clinical assets rather than top-line expansion. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that the firm reinvests all available capital and cash reserves into research, development, and clinical trials. Consequently, the overall growth and income profile is characterized by a reinvestment strategy focused entirely on advancing the JADE101 asset through clinical phases to achieve future commercialization potential rather than providing current income to shareholders.